On June 18th, the California Board of Pharmacy (CA BOP) held a regulation hearing on compounded drug preparations. McGuff’s management team, along with an estimated attendance of over 100 people, including medical professionals from diverse specialties, attended this three-hour subcommittee meeting. Their goal was to advocate for continued access to sterile compounded drugs from 503A compounding pharmacies.